A month has gone by since the last earnings report for Pfizer (PFE). Shares have lost about 1.9% in that time frame, outperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release,

There is no better period, given the volatility in the markets today, to rotate assets into dividend stocks, said Steven Cress, VP of Quantitative Strategy at Seeking Alpha. During Seeking Alpha’s Dividend Investing Forum virtual event,

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy rating on PFE stock.

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. It's no secret why Pfizer has not performed well recently. The company was never going to keep up those sales year in and year out.

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Explore more details here.

Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous

Says “I don’t think the Street” has adjusted yet and that “they should have a look on it.” The company says the rebates that Pfizer (PFE) will

(NYSE:PFE) shareholders, since the share price is down 43% in the last three years, falling well short of the market return of around 38%. While the last three years has been tough for Pfizer shareholders,

Bury's 'local plan' is being produced but massive housing projects planned for green land at areas such as Elton reservoir and Walshaw are not in its scope as 'the principle of development has been es

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE),

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, investing in gene therapy stocks like Pfizer (PFE), Sanofi (SNY), and Novartis AG (NVS) could be beneficial.